Evidence map›Paper›PMID 30416973›Full record

ArticleJournal of clinical & translational endocrinology2018

A higher blood glucose level pre-breakfast in comparison to bedtime is a contraindication for intensification of prandial insulin therapy in patients with type 2 diabetes - The impact of a negative BeAM value.

Thorsten Siegmund, Anja Borck, Ariel Zisman, Peter Bramlage, Stephan Kress

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical & translational endocrinology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Unleashing the Potential of Blood Glucose Monitoring Data With the Ambulatory Glucose Profile Report.Clinical diabetes : a publication of the American Diabetes Association · 2024
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Thorsten SiegmundStädt. Klinikum München GmbH, Klinikum Bogenhausen, Germany.
Anja BorckSanofi-Aventis Deutschland GmbH, Berlin, Germany.
Ariel ZismanThe Endocrine Center of Aventura, Aventura, FL, USA.
Peter BramlageInstitut für Pharmakologie und Präventive Medizin, Cloppenburg, Germany.
Stephan KressVinzentius-Krankenhaus, Landau, Germany.
Aventura Hospital and Medical Center · USIPPMed (Germany) · DEMünchen Klinik Bogenhausen · DESanofi (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsThe BeAM value refers to the difference between a patient's blood glucose level at bedtime (Be) and the following morning before breakfast (AM). The clinical impact of a negative BeAM value (AM blood glucose reading compared to that taken at bedtime) is unknown.

methodsT2DM patients of the OPAL and POC trials were pooled and their BeAM values calculated.

resultsFrom a total of 358 patients, 31 were calculated as having a negative BeAM value at baseline, while 182 had a high value. Patients in the negative BeAM group were younger, had shorter diabetes duration, and lower HbA1c levels. Fasting blood glucose levels were higher in the negative BeAM group, and these increased to a greater extent during the trial periods. No significant differences in hypoglycaemia occurrence were observed. Multivariate adjusted analysis indicated no association between a negative BeAM value and achievement of HbA1c < 7%, or composite endpoints that additionally included no hypoglycaemia and no weight gain.

conclusionsSupplementation of BOT with prandial insulin is not beneficial for patients who have a higher blood glucose reading before breakfast in comparison to before bedtime. Further investigation into the cause of the high morning reading in these patients is indicated.

Indexed as

Basal-plusGlargineGlulisinePrandial insulinType-2 diabetes

Identifiers

PMID30416973
PMCPMC6214867
OpenAlexW2898270969

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.